News for Kyowa Kirin Co., Ltd. (KYKOF)

Kura Oncology (KURA) grants inducement stock options to eight new employees. Stock options cover 141,750 shares with an exercise price of $5.60 per shar

PR NewswireTHOUSAND OAKS, Calif., June 23, 2025 MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Wei

PR NewswireTHOUSAND OAKS, Calif., June 18, 2025 MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for th

**media[647618]**

”“ CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients ”“ ”“ Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD

**media[643817,643818]**

”“ Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd ”“ ”“ Enco

**media[634801,634802]**

”“ Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th ”“ ”“ Updated dataset to be pre

**media[625851,625852]**

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. ( KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of prec

Kura Oncology (KURA) to participate in the Bank of America Securities 2025 Healthcare Conference. CEO Troy Wilson will engage in a fireside chat on May

PR NewswireTHOUSAND OAKS, Calif., May 1, 2025 THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for

**media[609493]**

”“ Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure ”“ ”“ Combination

PR NewswireTHOUSAND OAKS, Calif., April 25, 2025 Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif., April 25, 2025

PR NewswireTHOUSAND OAKS, Calif., April 11, 2025 First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Pro

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizi

**media[585963]**